下一代测序在转移性前列腺癌细针穿刺活检中的应用价值
该回顾性研究分析了2015至2024年间46例转移性前列腺癌细针穿刺活检样本,评估细胞块和/或涂片进行下一代测序(NGS)的效用。结果显示10例(22%)患者基于NGS结果改变了或可能改变治疗方案,NGS在部分患者中具有诊断和治疗价值。
要点
- NGS可确认转移性前列腺癌的起源并指导治疗选择。
- 22%的转移性前列腺癌FNA样本NGS结果影响治疗决策。
- NGS可识别CDK12、IDH1、BRCA2等可靶向的突变。
核心结论
- 在转移性前列腺癌的细胞学材料上进行NGS,对部分患者具有诊断和治疗效用,46例中10例(22%)基于NGS结果改变了或可能改变治疗方案。
研究设计与样本
- 回顾性综述了2015至2024年间45例患者的46例转移性前列腺癌细针穿刺活检病例,NGS在细胞块和/或涂片上进行。
主要发现
- 转移部位包括20例淋巴结、12例肝、5例肺、4例软组织、2例胸膜、2例骨和1例肾上腺。
- 10例患者(22%)基于NGS结果改变了或可能改变治疗。
- 1例低分化癌经TMPRSS2:ERG融合确认前列腺起源;1例初始诊断为转移性前列腺腺癌经NGS确认为肺起源。
- 1例NGS显示TP53和RB1突变,支持转化为高级别神经内分泌癌。
- 治疗改变或计划改变涉及2例CDK12突变、1例IDH1突变、3例BRCA2突变和1例PTEN及TP53突变患者。
临床怎么用
- 对转移性前列腺癌患者的细针穿刺细胞学材料可进行NGS,以辅助诊断起源和指导治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current American Society of Clinical Oncology guidelines state that patients with metastatic prostate cancer (MPC) should undergo germline and somatic DNA sequencing. The authors examined the utility of next-generation sequencing (NGS) on fine-needle aspiration (FNA) biopsies in which NGS was performed on cell block (CB) and/or smears. METHODS: A retrospective review was performed of cytology cases with diagnosis of MPC either before and/or after NGS on FNA material. Clinical and NGS data were obtained from the medical record. Androgen receptor, NKX3.1, INSM1, synaptophysin, chromogranin, Rb, PTEN, and Ki67 immunohistochemical stains were performed on CB if not originally done. RESULTS: Slides and NGS data were available for 46 MPC FNA biopsies from 45 patients from 2015 to 2024. Metastatic sites included 20 lymph node, 12 liver, five lung, four soft tissue, two pleura, two bone, and one adrenal gland. Ten patients (22%) had change or potential change in therapy based on NGS results. For one patient with poorly differentiated carcinoma previously thought to be urothelial, a TMPRSS2:ERG fusion confirmed prostatic origin. NGS confirmed lung origin for one patient diagnosed initially as metastatic prostatic adenocarcinoma. For one patient, NGS demonstrated TP53 and RB1 mutations, supporting transformation to high-grade neuroendocrine carcinoma. Change or potential change in therapy was planned for two patients with CDK12 mutations, one with IDH1 mutation, three with BRCA2 mutations, and one with PTEN and TP53 mutations. CONCLUSIONS: NGS on cytology material showed diagnostic and therapeutic utility in a subset of patients, with 10 of 46 patients (22%) having a change or potential in therapy based on NGS results.
引用
- Sirohi D, Cornelia Ding CK, Stohr BA, et al. The utility of next-generation sequencing in metastatic prostate cancer FNA biopsies. Cancer Cytopathol. 2025. PMID: 40847760. doi:10.1002/cncy.70038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。